Rösch AG Medizintechnik
Rösch AG Medizintechnik english

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Rhein Biotech and Rösch enter into strategic research collaboration Rhein Biotech N.V. (WKN 919 544),the world’s third largest manufacturer of hepatitis B vaccine, und Rösch Medizintechnik AG, specialised in the development, manufacture and marketing of needle-free injection systems announce the signing of a strategic research collaboration. The aim of the collaboration is to develop needle-free injection systems for use with selected vaccines from Rhein Biotech’s portfolio. The resulting technology will be available to Rhein Biotech via license from Rösch. The financial terms of the agreement were not disclosed. For further information please contact: Valerie Ward, Investor Relations Rhein Biotech N.V., Maastricht (NL) T: +31 (0)43 / 3 56 78 98 F: +31 (0)43 / 3 56 78 99 e: investor@rheinbiotech.com Brigita Morrissey and Jens Rossel, Investor Relations Rösch AG Medizintechnik, Berlin (D) T: +49 (0)30 / 66 79 15-37 od. -41 F: +49 (0)30 / 66 79 15-66 e: morrissey@roesch-ag.de end of ad hoc announcement (c) DGAP 14.08.2001 Issuer’s information/explanatory remarks concerning this ad hoc announcement: Dr. Daan Ellens, CEO of the Rhein Biotech Group: “The collaboration with Rösch is a further step in our current product strategy: to develop on the one hand new vaccines against mass diseases and on the other hand improved forms of existing products in order to enter new attractive markets. With Rösch we have found an experienced partner. The cost-saving concept of Rösch’s needle-free systems makes them suitable for use in Rhein Biotech’s main markets”. Andy Rösch, CEO of Rösch AG: Through agreements such as this, Rösch aims to explore new areas of application for its innovative needle-free drug delivery systems and to enhance growth of sales. This agreement clearly confirms the interest of the pharmaceutical and biotech industry in our technology. We are very pleased that Rhein Biotech has entered into this collaboration with us to develop more convenient delivery systems for their products. We feel sure that the Rösch technology is the right solution. Information about the companies Rhein Biotech is a global biotechnology group, which develops, produces and markets vaccines and therapeutic compounds based on its platform technologies. With Hepavax Gene, manufactured by its subsidiary GreenCross Vaccine, the Group is the world’s third largest producer of hepatitis B vaccine. Rhein Biotech currently markets 13 products reaching 75% of the world’s population. The Group employs over 300 people, one third of them in R&D. Rhein Biotech has been listed on the Neuer Markt (Frankfurt) since April 1999. Rösch AG Medizintechnik specialises in customer oriented medical technology and has a leading position in the development, manufacture and marketing of cost- effective needle-free drug delivery systems. The Company’s technology platform is designed to create disposable and reusable needle-free injection systems ROJEX(tm), INJEX(tm) which meet the requirements of patients, the medical profession and the pharmaceutical industry. The Company was founded in 1990 and is listed on the Neuer Markt (Frankfurt) since February 2000. With Headquarters in Berlin, the Rösch Group employs more than 75 people and markets its products in several European countries. For further information visit www.rheinbiotech.com as well as www.roesch-ag.de. ——————————————————————————– WKN: 529 140; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Stuttgart, Hannover 140835 Aug 01